Biotech Values

[DewDiligence]

ACHN Announces ACH-1625 Presentations at EASL

[ACH-0141625, which is mentioned in the first presentation below, is evidently another name for ACH-1625.]

http://finance.yahoo.com/news/Achillion-to-Present-ACH1625-pz-3326431561.html?x=0

›Tuesday March 16, 2010, 7:00 am EDT

NEW HAVEN, Conn., March 16, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "Virological Response, Safety, and Pharmacokinetic Profile Following Single- and Multiple-Dose Administration of ACH-0141625 Protease Inhibitor to Healthy Volunteers and HCV Genotype-1 Patients" has been accepted as a late breaking poster presentation at the International Liver Congress 2010 being held April 14-18 in Vienna, Austria.

Two additional abstracts on the compound's virology and hepatoselectivity titled “Preclinical Antiviral Activity, Combination and Resistance of ACH-1625, A Potent HCV NS3 Protease Inhibitor,” and “Characterization of the Hepatoselective Distribution of ACH-1625, a Potent, Clinical Stage HCV NS3 Protease Inhibitor” had previously been accepted for poster presentation.

Achillion's posters will be displayed from Thursday, April 15 at 8:00 a.m. through Saturday, April 17 at the end of the day's sessions.‹